Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have earned an average recommendation of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $29.67.

UPB has been the subject of several analyst reports. Wall Street Zen downgraded Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Truist Financial dropped their target price on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Upstream Bio in a research note on Wednesday, September 2nd.

Upstream Bio Stock Up 3.7%

NASDAQ:UPB opened at $5.36 on Friday. The company has a market cap of $293.57 million, a P/E ratio of -1.85 and a beta of 1.28. The firm’s 50 day moving average is $6.40 and its two-hundred day moving average is $7.65. Upstream Bio has a fifty-two week low of $4.99 and a fifty-two week high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The firm had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. Research analysts forecast that Upstream Bio will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

A number of large investors have recently bought and sold shares of the business. Walleye Capital LLC acquired a new position in shares of Upstream Bio during the 2nd quarter valued at about $3,450,000. Arrowstreet Capital Limited Partnership bought a new stake in Upstream Bio during the first quarter worth approximately $1,666,000. Deutsche Bank AG bought a new position in shares of Upstream Bio in the second quarter valued at approximately $1,671,000. BlackRock Inc. bought a new position in shares of Upstream Bio in the second quarter valued at approximately $25,973,000. Finally, Squarepoint Ops LLC lifted its stake in shares of Upstream Bio by 551.9% in the second quarter. Squarepoint Ops LLC now owns 290,904 shares of the company’s stock worth $2,013,000 after buying an additional 246,278 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company’s research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies.

Upstream Bio’s lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses.